The SDGs for management of related problems in renal replacement therapy
Renal Replacement Therapy is a peer-reviewed journal facilitating worldwide discussion of research and issues related to the study of renal replacement therapy.
RRT considers articles on all aspects of hemodialysis, peritoneal dialysis, blood purification, renal transplantation and regenerative medicine. In addition, the journal publishes content in wider fields such as chronic kidney disease (CKD), acute kidney injury (AKI), critical care medicine and intensive care, bone and mineral metabolism, anemia and iron metabolism, infection, cardiac disease, cerebral disease, diabetes mellitus, hypertension, nutrition, and related social issues. Contributions are encouraged from a global perspective across many disciplines.
The 17th Annual Meeting of the Japanese Society of Nephrology and Pharmacotherapy
28-29 October 2023, WINC AICHI
The 26th Annual Meeting of Japan Academy of Nephrology Nursing
18-19 November 2023, TKP GardenCity Sendai
The 44th Japanese Society for Pediatrics Renal Failure
30 November-1 December 2023, Hotel Grande Hagakure
The 14th Annual Meeting of the Japanese Society of Renal Rehabilitation
16-17 March 2024, Toki Messe, Niigata Convention Center
The 50th Annual Meeting of Japanese Society for Technology of Blood purification
12-14 April 2024, Kawagoe Prince Hotel
The 69th Annual Meeting of the Japanese Society for Dialysis Therapy
7-9 June 2024, Pacifico Yokohama
The 35th Annual Meeting of the Japan Society for Blood Purification Critical Care
19-20 October 2024, Kofu Kinenbi Hotel
The 27th Annual Meeting of Japan Academy of Nephrology Nursing
9-10 November 2024, Toyama International Conference Center
The 30th Annual Meeting of the Japanese Society for Peritoneal Dialysis
16-17 November 2024, Fukuoka Convention Center
The 58th Annual Meeting of Japanese Society for Clinical Renal Transplantation
6-8 February 2025, Hiroshima City
The 15th Annual Meeting of the Japanese Society of Renal Rehabilitation
15-16 March 2025, Pacifico Yokohama
The 70th Annual Meeting of the Japanese Society for Dialysis Therapy
27-29 June 2025, Osaka International Convention Center
Please use the online submission system to submit your manuscript. For all enquiries about the journal, please access the site and click Contact Us.
Renal Replacement Therapy is the official publication of the following societies:
The 67th Annual Meeting of the Japanese Society for Dialysis Therapy was held in June 2022, under the theme “Seeking SDGs for Dialysis Therapy.” The main goal of this conference was to identify sustainable goals for dialysis treatment and consider the best means of achieving them.
In commemoration of the success of the meeting, we are pleased to announce that the article collection entitled “The SDGs for management of related problems in renal replacement therapy” has now published in the spring of 2023.
In this article collection, we invited nine leading researchers to reaffirm our commitment to identifying the various problems and to achieving these goals through sustained efforts.
Hemodialysis-associated pruritus (HAP) affects a high percentage of hemodialysis patients, leading to a decrease in their quality of life and poor survival outcomes. This study explored the use of a synthetic polymer membrane, PMF-21A, for online hemodiafiltration (OHDF) to address HAP. OHDF with PMF-21A could be a more effective treatment for Hemodialysis-associated pruritus, especially in addressing daytime pruritus.
See this article:
TAVI appears to be a viable alternative treatment for Japanese hemodialysis patients with severe AS. It offers similar outcomes and complication rates as SAVR during a one-year observation period. This suggests that TAVI is a reasonable choice for this patient population, providing an effective and less invasive therapy for aortic valve stenosis.
The Japanese Society for Dialysis Therapy has been conducting the survey annually since 1968. The results provide a comprehensive picture of dialysis therapy in Japan. In 2019, the number of chronic hemodialysis patients continued to increase, albeit at a slower rate, reaching an estimated 344,640. The elderly population on hemodialysis is growing, with incident patients averaging 70.42 years.
See this article:
The outbreak of novel coronavirus disease 2019 (COVID-19) led to a worldwide pandemic. Both failure to recover and poor prognoses for COVID-19 have been reported in patients with end-stage renal disease (ESRD) treated with renal replacement therapy and in the elderly. ESRD patients in Japan are one of the oldest populations in the world. Accordingly, we decided to launch the special collection on COVID-19 in RRT, the official journal of several academic societies with a focus on renal replacement therapy. We hope that this collection will support you in your own efforts.
Renal Replacement Therapy publishes valuable data based on clinical practice guidelines, statistical surveys, and epidemiological studies. This collection offers easy access to these resources. All papers in the collection are frequently accessed and highly cited. Moreover, the full text is published free of charge using an open journal CC-BY format. By pursuing this approach, our goal is to contribute as much as possible to the renal replacement therapy community while also responding to your interests.
Dr. Takashi Shigematsu, Editor-in-Chief
Dr. Takashi Shigematsu is currently the emeritus professor of the department of nephrology at the Wakayama Medical University School of Medicine, Japan. He is now actively working as Director of Division of Nephrology and Clinical Research Center in Rinku General Medical Center. He is also a member of the International Society of Nephrology and the American Society of Nephrology.
His research interests focus on Mineral and Bone Disorder associated with chronic kidney disease (CKD) including vascular calcification, Senescence. Renal Anemia is another his major interest. In addition, he has been investigating and working in the fields of hemodialysis and vascular access, peritoneal dialysis, blood purification medicine in acute kidney injury, and kidney transplantation.
Prof. Masanori Abe, Deputy Editor
Professor and Chair of the Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Prof. Abe also serves as the Chief Director of Blood Purification Center of Nihon University Itabashi Hospital. His professional interests include Nephrology and Renal Replacement Therapy.
If your manuscript could benefit from improvements to the English language, you should have your manuscript reviewed by someone who is fluent in English. For a collection of free resources to help with writing in English please visit here. If you would like professional help, we recommend our affiliates Nature Research Editing Service and American Journal Experts for help with English usage. BMC authors receive 10% off their first submission to either service. Please note that use of an editing service is neither a requirement nor a guarantee of publication.
2022 Citation Impact
1.2 - 2-year Impact Factor
0.703 - SNIP (Source Normalized Impact per Paper)
0.438 - SJR (SCImago Journal Rank)
8 days submission to first editorial decision for all manuscripts (Median)
150 days submission to accept (Median)
91 Altmetric mentions